All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Constantine Tam
Professor Constantine Tam is Director of Haematology at the St Vincent’s Hospital, Melbourne, AU, as well as Disease Group Lead for chronic lymphocytic leukemia and low-grade lymphoma at the Victorian Comprehensive Cancer Centre, Melbourne, AU. He is an internationally recognized expert in targeted therapies for B-cell malignancies and leads multiple clinical trials for the novel BTK inhibitor, BGB-3111, as well as the first clinical trial in the world to combine ibrutinib and venetoclax.
Prof. Tam graduated MBBS (Hons) in 1998, completing his hematology training at the University of Melbourne, Melbourne, AU, and a Leukemia Fellowship at The University of Texas MD Anderson Cancer Center, Texas, US. He was awarded a research Doctor of Medicine in 2009 at the University of Melbourne.
Prof. Tam has authored 149 papers as well as numerous book chapters and receives research funding from the Victorian Cancer Agency, Australian Government National Health and Medical Research Council (NHRMC), Leukemia and Lymphoma Society, American Institute for Cancer Research (AICR), St Vincent’s Curran Endowment Fund, CLL Global Research Foundation, The Viertel Charitable Foundation, and the CASS Foundation. In 2013, Prof. Tam was awarded the Herman Clinical Fellowship for Translational Cancer Research by the University of Melbourne.
Positions of responsibility/awards:
- Herman Fellowship in Translational Cancer Research from the University of Melbourne, 2013
- Teaching Excellence Award from the University of Melbourne, 2010
- Sylvia and Charles Viertel Foundation Clinical Investigator Fellowship, 2009
- Merit Award from the American Society of Clinical Oncology (ASCO), 2007 and 2008
- Travel Award from the American Society of Hematology (ASH), 2007
- Janice Davis Singletary Fellowship for Lymphoma Research from MD Anderson Cancer Center, 2007
- MD Anderson Cancer Center Fellowship in Patient-Oriented Research in CLL, 2006
- Young Investigator Award, Haematology Society of Australia and New Zealand, 2005 and 2006
- Member of ASH, ASCO, the European Hematology Association (EHA), and the American Association for Cancer Research (AACR)
- On the editorial boards of Blood Advances and Leukemia & Lymphoma